Analytical Data
-
Gene name
IL36G
- Application
-
Alternative Names
IL36G;IL1E;IL1F9;IL1H1;Interleukin-36 gamma
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZH8
-
Expression Region
1-169aa
-
AA Sequence
MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND
-
Molecular Weight
18.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL36G, a member of the interleukin-36 (IL-36) cytokine family, plays a significant role in the immune response and inflammatory processes, particularly in relation to skin and autoimmune diseases. Originally identified in keratinocytes, IL36G is involved in the promotion of Th17 cell responses and has been linked to various conditions such as psoriasis, rheumatoid arthritis, and other inflammatory skin disorders. Its expression is tightly regulated, and aberrant levels of IL36G can lead to dysregulation of normal immune responses, contributing to chronic inflammation. Recent studies have highlighted the potential of IL36G as a therapeutic target, with emphasis on its role in modulating inflammation and its interaction with other cytokines in the inflammatory milieu. Research on recombinant IL36G protein has focused on characterizing its biological functions, elucidating its signaling pathways, and exploring its potential as a biomarker for inflammatory diseases. Additionally, the investigation of IL36G in various experimental models has opened up avenues for the development of novel therapeutic strategies, particularly in conditions characterized by Th17-mediated inflammation. Understanding the precise mechanisms of IL36G action and its role in the immune landscape remains a critical area of research, paving the way for innovative approaches to target inflammatory diseases more effectively.
